Published online 22 September 2009
Haematologica, Vol 95, Issue 1, 135-143 doi:10.3324/haematol.2008.001628
Copyright © 2010 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lim, S. H.
Right arrow Articles by Cragg, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lim, S. H.
Right arrow Articles by Cragg, M. S.

Malignant Lymphomas

Anti-CD20 monoclonal antibodies: historical and future perspectives

Sean H. Lim, Stephen A. Beers, Ruth R. French, Peter W.M. Johnson, Martin J. Glennie, Mark S. Cragg

Tenovus Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, UK

Correspondence: Mark S Cragg, Tenovus Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, SO16 6YD, UK. E-mail: msc{at}soton.ac.uk

Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 therapy was introduced.

Key words: CD20, monoclonal antibodies, lymphoma, immunotherapy.




This article has been cited by other articles:


Home page
 BloodHome page
S. A. Beers, R. R. French, H. T. C. Chan, S. H. Lim, T. C. Jarrett, R. M. Vidal, S. S. Wijayaweera, S. V. Dixon, H. Kim, K. L. Cox, et al.
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
Blood, June 24, 2010; 115(25): 5191 - 5201.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. A. Beers, M. S. Cragg, and M. J. Glennie
Complement: help or hindrance?
Blood, December 24, 2009; 114(27): 5567 - 5568.
[Full Text] [PDF]

Home page
 BloodHome page
M. Introna and J. Golay
Complement in antibody therapy: friend or foe?
Blood, December 17, 2009; 114(26): 5247 - 5248.
[Full Text] [PDF]